Please login to the form below

Not currently logged in
Email:
Password:

IBS

This page shows the latest IBS news and features for those working in and with pharma, biotech and healthcare.

Ardelyx gets second kidney disease trial win for tenapanor

Ardelyx gets second kidney disease trial win for tenapanor

Shares in Ardelyx rocketed 72% on the back of the new study on the prospect of a second indication for tenapanor to follow constipation associated with IBS, which is under review

Latest news

More from news
Approximately 4 fully matching, plus 94 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... However, FiberOne poked fun at doctors and their scepticism of the legitimacy of IBS.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Positive results from a phase Ib dose-escalation study were

  • Deal Watch January 2017 Deal Watch January 2017

    Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.

  • Deal Watch January 2016 Deal Watch January 2016

    TEN-010, the lead, is a small molecule BET inhibitor that is in two phase Ib oncology studies. ... It is expected that $30m of payments will fall in 2016 relating to the phase Ib studies for SER 262 and a late stage study for SER 109 in CDI.

  • Pharma deals in February 2015 Pharma deals in February 2015

    diarrhoea (IBS-D) label be successful, this figure could rise to $2bn.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Diagnosing MS: are we getting it right?

    MS symptoms can be hard to pin down. I’ve heard bladder issues being attributed to “women’s problems”, bowel issues to irritable bowel syndrome (IBS), and fatigue to stress and

  • Irritable Bowel Syndrome (IBS) patient insights Irritable Bowel Syndrome (IBS) patient insights

    underestimate the severity of IBS symptoms .  understate global effect on quality of life . ... 1)  . "IBS is a real gastrointestinal condition; it is not ‘in your head’.".

  • IGNIFI IGNIFI

    Irritable Bowel Syndrome (IBS) patient insights. ... It’s common. It’s debilitating. We’re talking about IBS. In this issue of MAGNIFI, we explore the insights of patients suffering with IBS, while also looking into research around

  • Shifting perceptions of the use of probiotics in IBS Management

    Our client was planning to launch an over-the-counter (OTC) probiotics product for the purposes of improving IBS management and wanted to understand current perceptions, practices and usage amoungst a

  • Research Partnership

    We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we provide custom solutions and strategic recommendations that go beyond research, helping our

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics